NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Roche's companion diagnostic test for Tarceva (erlotinib), Roche announced Tuesday night.

Roche also said that FDA approved Tarceva as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have certain epidermal growth factor receptor mutations as detected by the Cobas EGFR Mutation Test.

Tarceva is jointly marketed in the US by Roche's Genentech business and Astellas Pharma US, a subsidiary of Tokyo-based Astellas Pharma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.